Seaport Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 3, 2026
SPTX$21.97+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)(Unaudited)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(88,008) | $(28,202) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 39,432 | 3,375 |
| Depreciation expense | 52 | 77 |
| Amortization of operating lease right-of-use assets | 656 | 592 |
| Net amortization of premiums and discounts on investments | (582) | (2,019) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (433) | (5,494) |
| Other non-current assets | - | (1,191) |
| Accounts payable | 3,690 | (2,604) |
| Related party payable | (7) | (283) |
| Accrued expenses and other current liabilities | (461) | 709 |
| Operating lease liability | (652) | (490) |
| Net cash used in operating activities | (46,313) | (35,530) |
| Investing activities | ||
| Purchases of investments | (300,652) | (304,171) |
| Proceeds from maturities of investments | 125,000 | 77,500 |
| Purchases of property and equipment | — | (323) |
| Net cash used in investing activities | (175,652) | (226,994) |
| Financing activities | ||
| Proceeds from initial public offering, net of underwriting discounts and commissions and deferred offering costs | 239,338 | — |
| Proceeds from exercise of stock options | 807 | — |
| Net cash provided by financing activities | 240,145 | — |
| Effect of exchange rates on cash and cash equivalents | 1 | — |
| Net increase (decrease) in cash and cash equivalents | 18,181 | (262,524) |
| Cash, cash equivalents, and restricted cash, beginning of period | 46,496 | 309,553 |
| Cash, cash equivalents, and restricted cash, end of period | $64,677 | $47,029 |
| Supplemental disclosure of non-cash operating, financing, and investing information: | ||
| Operating lease right-of-use assets obtained in exchange for lease liabilities | $584 | $1,114 |
| Deferred offering costs included in accounts payable and accrued expenses | $97 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.